## Local Government Mandate Statement Kentucky Legislative Research Commission 2024 Regular Session

## **REVISED 3/1/2024**

**Part I: Measure Information** 

Bill Request #: 179	2		
Bill #: HB 534 HCS	<u>S 1</u>		
Document ID #: 74	12		
Bill Title:	AN ACT relating to add	diction treatment.	
Sponsor: Representative Robert Duvall			
Unit of Government:		X County X Consolidated Local	Unified Local
Office(s) Impacted: All offices that offer health insurance for their employees.			
Requirement: X	Mandatory Opt	tional	
Effect on Powers & Duties:	Modifies Existing	Adds New E	liminates Existing

## Part II: Bill Provisions and the Estimated Fiscal Impact Relating to Local Government

Section 2 of HB 534 HCS 1 amends KRS 304.17A-611 to prohibit health benefit plans from conducting a prospective or concurrent review for a prescription drug that contains an opioid antagonist.

HB 534 HCS 1 may have an indeterminable and likely negligible impact on local governments. There are already drugs with similar prohibitions that currently exist—Methadone, Buprenorphine, and Naltrexone. By preventing health benefit plans from conducting prospective or concurrent reviews for prescriptions drug that contains an opioid antagonist, there may be a smaller administrative burden on health benefit plans cutting wait times for patients with prescriptions for those drugs; however, that is unknown at this time.

LRC staff also reached out to the Kentucky Association of Counties (KACo). KACo believes this bill would have a negative fiscal impact on counties; however, KACo believes the impact would be minimal.

LRC staff also reached out to the Kentucky League of Cities (KLC). KLC does not believe HB 534 would have a fiscal impact. .

**Data Source(s):** LRC Staff

Preparer: Bart Liguori (MS) Reviewer: KHC Date: 3/1/24